Krystal Biotech, Inc. $KRYS Stock Position Increased by Fifth Third Bancorp

Fifth Third Bancorp raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 3,958.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,925 shares of the company’s stock after purchasing an additional 5,779 shares during the period. Fifth Third Bancorp’s holdings in Krystal Biotech were worth $1,531,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Greenline Wealth Management LLC acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at approximately $34,000. Sound Income Strategies LLC boosted its position in shares of Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares during the period. UMB Bank n.a. boosted its position in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares during the period. Global Retirement Partners LLC grew its holdings in Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after buying an additional 142 shares in the last quarter. Finally, Danske Bank A S bought a new position in Krystal Biotech in the 3rd quarter worth approximately $35,000. Institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares of the company’s stock, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by insiders.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $327.50 on Friday. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54. The firm has a market capitalization of $9.65 billion, a PE ratio of 43.78 and a beta of 0.50. The company’s 50 day simple moving average is $333.19 and its 200 day simple moving average is $292.22.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings cut Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Bank of America increased their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $360.67.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.